

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
	<title>Safety warnings and messages for medicines</title>
	<link>http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&amp;nodeId=100806</link>
 

<item>
<title>Information sent to healthcare professionals in April about the safety of medicines</title>
<pubDate>Tue, 01 May 2012 14:46:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON152559 </link>
	 <description><![CDATA[Copies of letters sent to healthcare professionals in April 2012 to inform of new safety information and advice.<br/> ]]></description>
	 </item>
 

<item>
<title>Information sent to healthcare professionals in March about the safety of medicines</title>
<pubDate>Mon, 02 Apr 2012 09:37:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON146914 </link>
	 <description><![CDATA[•	Copies of letters sent to healthcare professionals in March 2012 to inform of new safety information and advice.<br/> ]]></description>
	 </item>
 

<item>
<title>Information sent to healthcare professionals in February about the safety of medicines</title>
<pubDate>Tue, 27 Mar 2012 08:47:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON146475 </link>
	 <description><![CDATA[Copies of letters sent to healthcare professionals in February 2012 to inform of new safety information and advice.<br/> ]]></description>
	 </item>
 

<item>
<title>Information sent to healthcare professionals in January about the safety of medicines</title>
<pubDate>Thu, 02 Feb 2012 10:45:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON143507 </link>
	 <description><![CDATA[Copies of letters sent to healthcare professionals in January 2012 to inform of new safety information and advice.<br/> ]]></description>
	 </item>
 

<item>
<title>Information sent to healthcare professionals in December about the safety of medicines</title>
<pubDate>Sun, 08 Jan 2012 13:33:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON140590 </link>
	 <description><![CDATA[Copies of letters sent to healthcare professionals in December 2011 to inform of new safety information and advice. This month's issues include risk of increased blood pressure and heart rate when using Strattera and information on weight gain, hyperglycaemia, and metabolic risk associated with Seroquel.  <br/> ]]></description>
	 </item>
 

<item>
<title>European Medicines Agency starts review of aliskiren-containing medicines following termination of ALTITUDE study - interim advice provided</title>
<pubDate>Sun, 08 Jan 2012 13:27:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON137929 </link>
	 <description><![CDATA[Routine (non-urgent) review is recommended for patients taking aliskiren-containing medicines. Routine (non-urgent) review is recommended for patients taking aliskiren-containing medicines. Aliskiren is approved for the treatment of essential hypertension.<br/> ]]></description>
	 </item>
 

<item>
<title>Information sent to healthcare professionals in November about the safety of medicines</title>
<pubDate>Fri, 02 Dec 2011 10:55:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON137675 </link>
	 <description><![CDATA[Copies of letters sent to healthcare professionals in November 2011 to inform of new safety information and advice. This month's issues include advice regarding Vectibix and Caelyx.<br/> ]]></description>
	 </item>
 

<item>
<title>Liquid paracetamol for children: Revised UK dosing instructions have been introduced</title>
<pubDate>Wed, 23 Nov 2011 11:01:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON134919 </link>
	 <description><![CDATA[A UK review of dosing instructions for children's liquid paracetamol products has led to revisions which will clarify the most effective dose to be given to a child according to their age.<br/> ]]></description>
	 </item>
 

<item>
<title>Information sent to healthcare professionals in August about the safety of medicines</title>
<pubDate>Thu, 03 Nov 2011 16:00:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON128962 </link>
	 <description><![CDATA[This page provides links to safety letters sent out in August 2011. The products mentioned are: Vimpat, Sprycel, Mabthera, Tisseel Lyo and Tisseel Ready to use (fibrin sealant)<br/> ]]></description>
	 </item>
 

<item>
<title>Information sent to healthcare professionals in October about the safety of medicines</title>
<pubDate>Thu, 03 Nov 2011 14:50:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON134744 </link>
	 <description><![CDATA[Letters sent to healthcare professionals in October 2011 to inform of new safety information and advice.<br/> ]]></description>
	 </item>
 

<item>
<title>Information sent to healthcare professionals in September about the safety of medicines</title>
<pubDate>Mon, 03 Oct 2011 14:21:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON131853 </link>
	 <description><![CDATA[This page provides a link to a safety letter sent out in September 2011. The product mentioned is Nplate (romiplostim).<br/> ]]></description>
	 </item>
 

<item>
<title>Non-steroidal anti-inflammatory drugs (NSAIDs) and risk of heart problems</title>
<pubDate>Thu, 29 Sep 2011 09:53:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON129228 </link>
	 <description><![CDATA[Hull York Medical School has led an international review which reports that the use of popular non-steroidal anti-inflammatory drugs, such as diclofenac can increase the risk of heart attack or stroke by a third.<br/> ]]></description>
	 </item>
 

<item>
<title>Reboxetine: A review of the benefits and risks</title>
<pubDate>Wed, 14 Sep 2011 15:33:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON129106 </link>
	 <description><![CDATA[A UK and Europe-wide review of scientific data has confirmed that reboxetine has benefit over placebo in its authorised indication for patients with severe or very severe depression.<br/> ]]></description>
	 </item>
 

<item>
<title>Pseudoephedrine and ephedrine: Managing the risk of misuse of medicines - July 2010 update</title>
<pubDate>Tue, 30 Aug 2011 15:05:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON090754 </link>
	 <description><![CDATA[None<br/> ]]></description>
	 </item>
 

<item>
<title>Pseudoephedrine- and ephedrine-containing medicines: 2011 review of actions to manage the risk of misuse</title>
<pubDate>Tue, 30 Aug 2011 15:04:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON126277 </link>
	 <description><![CDATA[This Public Assessment Report published in August 2011 presents a review of the impact of the legal measures put in place from 2010 – 2011 to manage the risk of misuse of cold and flu medicines containing pseudoephedrine and ephedrine.<br/> ]]></description>
	 </item>
 

<item>
<title>Information sent to healthcare professionals in July about the safety of medicines</title>
<pubDate>Wed, 03 Aug 2011 11:54:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON125967 </link>
	 <description><![CDATA[This page provides links to safety letters sent out in July 2011. The products mentioned are: Thyrogen, pioglitazone, Cardioxane and Multaq.<br/> ]]></description>
	 </item>
 

<item>
<title>New advice on risk of bladder cancer with the anti-diabetic drug pioglitazone (Actos▼, Competact▼)</title>
<pubDate>Fri, 22 Jul 2011 15:34:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON123285 </link>
	 <description><![CDATA[A review by the European Medicines Agency has found there is a small increased risk of bladder cancer associated with pioglitazone use.<br/> ]]></description>
	 </item>
 

<item>
<title>Information sent to healthcare professionals in June about the safety of medicines</title>
<pubDate>Tue, 05 Jul 2011 09:28:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON123090 </link>
	 <description><![CDATA[Copies of letters sent to healthcare professionals in June 2011 to inform of new safety information and advice.<br/> ]]></description>
	 </item>
 

<item>
<title>Information sent to healthcare professionals in January about the safety of medicines</title>
<pubDate>Thu, 02 Jun 2011 15:30:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON106073 </link>
	 <description><![CDATA[Copies of letters sent to healthcare professionals in January 2011, to inform of new safety information and advice.<br/> ]]></description>
	 </item>
 

<item>
<title>Information sent to healthcare professionals in December about the safety of medicines</title>
<pubDate>Thu, 02 Jun 2011 15:11:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON105736 </link>
	 <description><![CDATA[Copies of letters sent to healthcare professionals in December 2010, to inform of new safety information and advice.<br/> ]]></description>
	 </item>
 

<item>
<title>Current key information on the combined oral contraceptive, Yasmin - May 2011</title>
<pubDate>Wed, 01 Jun 2011 15:05:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON117560 </link>
	 <description><![CDATA[Current information on the risks and benefits of Yasmin following a recent analysis of available epidemiological data.<br/> ]]></description>
	 </item>
 

<item>
<title>Information sent to healthcare professionals in May about the safety of medicines</title>
<pubDate>Wed, 01 Jun 2011 14:35:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON120200 </link>
	 <description><![CDATA[Copies of letters sent to healthcare professionals in May 2011 to inform of new safety information and advice on medicines.<br/> ]]></description>
	 </item>
 

<item>
<title>Information sent to healthcare professionals in April about the safety of medicines</title>
<pubDate>Tue, 03 May 2011 16:08:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON117263 </link>
	 <description><![CDATA[Copies of letters sent to healthcare professionals in April 2011, including information on Onsenal (celecoxib), Efient (prasugrel),and Revlimid (lenalidomide)<br/> ]]></description>
	 </item>
 

<item>
<title>Information sent to healthcare professionals in March about the safety of medicines</title>
<pubDate>Thu, 31 Mar 2011 14:50:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON111795 </link>
	 <description><![CDATA[Copies of letters sent to healthcare professionals in March 2011, to inform of new safety information and advice.<br/> ]]></description>
	 </item>
 

<item>
<title>Information sent to healthcare professionals in February about the safety of medicines - update</title>
<pubDate>Thu, 10 Mar 2011 15:58:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON111461 </link>
	 <description><![CDATA[A letter about Lucentis (ranizumab) has been added to this monthly list of letters to healthcare professionals.<br/> ]]></description>
	 </item>
</channel>
</rss>
<!-- the HEAD element is required by SiteStudio
	<head><script language="JavaScript">
   var _U = "undefined";
   var g_HttpRelativeWebRoot = "/home/";
   var SSContributor = false;
   var SSForceContributor = false;
   var SSHideContributorUI = false;
   var ssUrlPrefix   = "/";
   var g_navNode_Path = new Array();
       g_navNode_Path[0] = '5';
       g_navNode_Path[1] = '338';
       g_navNode_Path[2] = '100806';
       g_navNode_Path[3] = '100959';
   var g_ssSourceNodeId = "100959";
   var g_ssSourceSiteId = "5";
   var g_strLanguageId = "en";
</script>
<script id="SSNavigationFunctionsScript" language="javascript" type="text/javascript" src="/home/websites/5/sitenavigationfunctions.js"></script>
<script id="SSNavigationScript" language="javascript" type="text/javascript" src="/home/websites/5/sitenavigation.js"></script>

	<script type="text/javascript" src="/home/resources/wcm/sitestudio/wcm.toggle.js"></script>
	<script type="text/javascript" src="/home/resources/sitestudio/ssajax/ssajax.js"></script>

	</head>
-->


